Related Experiment Video
Updated: Feb 2, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Statins as secondary preventives in patients with intracerebral hemorrhage
Signild Åsberg1, Bahman Farahmand2, Karin M Henriksson1
1Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Insights
Statin therapy after intracerebral hemorrhage may reduce death risk without increasing recurrent hemorrhage. This study offers reassurance for using statins in stroke survivors, indicating potential safety and benefits in secondary stroke prevention.
Area of Science:
- Neurology
- Cardiology
- Public Health
Background:
- Statins are crucial for secondary stroke prevention.
- Concerns exist regarding statin use increasing intracerebral hemorrhage (ICH) risk.
- The safety of initiating or continuing statins post-ICH remains unclear.
Purpose of the Study:
- To investigate the association between statin use and outcomes after a first intracerebral hemorrhage.
- To assess risks of recurrent ICH, general stroke, and death in patients treated with statins post-ICH.
Main Methods:
- Observational study of 6082 patients with first ICH (2004-2009).
- Data sourced from the Swedish Stroke Register and national registers.
- Propensity score and multivariable analysis used to adjust for confounding factors.
Main Results:
- 18% of patients received statins at discharge.
- Statin use was linked to a reduced risk of death (aHR 0.71).
- No significant association found between statin use and recurrent ICH (aHR 0.82).
Conclusions:
- Statin therapy appears safe for some patients post-intracerebral hemorrhage.
- Statin use is associated with decreased mortality after ICH.
- Evidence suggests statins do not elevate the risk of recurrent intracerebral hemorrhage.
Background:
Statins are important components of secondary stroke prevention, but there is a concern they may increase the risk of intracerebral hemorrhage. Although this risk may have been overestimated, there is still an open question whether statin therapy should be continued, or even initiated, in patients who have had a recent intracerebral hemorrhage.
Aim:
Our aim was to investigate the risk of statin use after an intracerebral hemorrhage with respect to recurrent intracerebral hemorrhage, stroke in general, and death.
Methods:
This observational study was based on patients with a first intracerebral hemorrhage in 2004 through 2009. Clinical characteristics, index intracerebral hemorrhage, and recurrent intracerebral hemorrhages were identified by the Swedish Stroke Register; additional data on comorbidities and vital status were retrieved through record linkages to national registers. A propensity score for the likelihood of receiving statins at discharge was developed and used with other established risk factors in a multivariable analysis.
Results:
Of 6082 intracerebral hemorrhage patients (mean age 69.6 years), 1097 (18%) were prescribed statins at discharge. During the follow-up (mean 3.1 years), 1434 (23.6%) deaths and 234 (3.8%) recurrent intracerebral hemorrhages were observed. Statin therapy was associated with a reduced risk of death (adjusted hazard ratio: 0.71; 95% confidence interval: 0.60-0.84) but not with the risk of recurrent intracerebral hemorrhage (adjusted hazard ratio: 0.82; 95% confidence interval: 0.55-1.22).
Conclusions:
This study provides some reassurance that statins may be safe to use, in at least some patients, after an intracerebral hemorrhage. In patients with intracerebral hemorrhage, statin use was associated with a reduced risk of death, without an increased risk of recurrent intracerebral hemorrhage.
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Secondary Healthcare System
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Primary and Secondary Growth in Roots and Shoots
Cancer Prevention
Some...

